162 related articles for article (PubMed ID: 38500772)
1. [Proteasome inhibitors in treatment of multiple myeloma].
Kubiczková L; Matějíková J; Sedlaříková L; Kryukov F; Hájek R; Sevčíková S
Klin Onkol; 2013; 26(1):11-8. PubMed ID: 23528167
[TBL] [Abstract][Full Text] [Related]
2. Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells.
Pelon M; Krzeminski P; Tracz-Gaszewska Z; Misiewicz-Krzeminska I
Front Pharmacol; 2024; 15():1351565. PubMed ID: 38500772
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib- and carfilzomib-resistant myeloma cells show increased activity of all three arms of the unfolded protein response.
Kubicki T; Bednarek K; Kostrzewska-Poczekaj M; Luczak M; Lewandowski K; Gil L; Jarmuz-Szymczak M; Dytfeld D
Am J Cancer Res; 2022; 12(7):3280-3293. PubMed ID: 35968359
[TBL] [Abstract][Full Text] [Related]
4. The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells.
Kraus M; Bader J; Geurink PP; Weyburne ES; Mirabella AC; Silzle T; Shabaneh TB; van der Linden WA; de Bruin G; Haile SR; van Rooden E; Appenzeller C; Li N; Kisselev AF; Overkleeft H; Driessen C
Haematologica; 2015 Oct; 100(10):1350-60. PubMed ID: 26069288
[TBL] [Abstract][Full Text] [Related]
5. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
[TBL] [Abstract][Full Text] [Related]
6. The proteasome and proteasome inhibitors in multiple myeloma.
Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Anderson KC; Richardson PG
Cancer Metastasis Rev; 2017 Dec; 36(4):561-584. PubMed ID: 29196868
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of P-Glycoprotein Does Not Increase the Efficacy of Proteasome Inhibitors in Multiple Myeloma Cells.
Mynott RL; Wallington-Beddoe CT
ACS Pharmacol Transl Sci; 2021 Apr; 4(2):713-729. PubMed ID: 33860196
[TBL] [Abstract][Full Text] [Related]
8. Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors.
Sogabe K; Nakamura S; Higa Y; Miki H; Oda A; Maruhashi T; Sumitani R; Oura M; Takahashi M; Nakamura M; Maeda Y; Hara T; Yamagami H; Fujii S; Kagawa K; Ozaki S; Kurahashi K; Endo I; Aihara KI; Nakaue E; Hiasa M; Teramachi J; Harada T; Abe M
Int J Hematol; 2024 Mar; 119(3):303-315. PubMed ID: 38245883
[TBL] [Abstract][Full Text] [Related]
9. Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma.
Bandini C; Mereu E; Paradzik T; Labrador M; Maccagno M; Cumerlato M; Oreglia F; Prever L; Manicardi V; Taiana E; Ronchetti D; D'Agostino M; Gay F; Larocca A; Besse L; Merlo GR; Hirsch E; Ciarrocchi A; Inghirami G; Neri A; Piva R
Exp Hematol Oncol; 2023 Aug; 12(1):71. PubMed ID: 37563685
[TBL] [Abstract][Full Text] [Related]
10. The STAT3 inhibitor stattic overcome bortezomib-resistance in multiple myeloma via decreasing PSMB6.
Yuan C; Yuan M; Li W; Cheng H; Luo J; Zhang Q; Shi M; Niu M; Yang J; Sun Z; Yan Z; Xu K; Li Z; Yao Y
Exp Cell Res; 2023 Aug; 429(1):113634. PubMed ID: 37207970
[TBL] [Abstract][Full Text] [Related]
11. Euchromatic Histone Lysine Methyltransferase 2 Inhibition Enhances Carfilzomib Sensitivity and Overcomes Drug Resistance in Multiple Myeloma Cell Lines.
Mereu E; Abbo D; Paradzik T; Cumerlato M; Bandini C; Labrador M; Maccagno M; Ronchetti D; Manicardi V; Neri A; Piva R
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190128
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitor bortezomib stabilizes and activates p53 in hematopoietic stem/progenitors and double-negative T cells in vivo.
Xue Y; San Luis B; Dress RJ; Murad KBA; Ginhoux F; Barker N; Lane D
Proc Natl Acad Sci U S A; 2023 Mar; 120(13):e2219978120. PubMed ID: 36940336
[TBL] [Abstract][Full Text] [Related]
13. Molecular Features of the Mesenchymal and Osteoblastic Cells in Multiple Myeloma.
Iannozzi NT; Marchica V; Toscani D; Burroughs Garcìa J; Giuliani N; Storti P
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555090
[TBL] [Abstract][Full Text] [Related]
14. The deubiquitinase OTUD1 regulates immunoglobulin production and proteasome inhibitor sensitivity in multiple myeloma.
Vdovin A; Jelinek T; Zihala D; Sevcikova T; Durech M; Sahinbegovic H; Snaurova R; Radhakrishnan D; Turi M; Chyra Z; Popkova T; Venglar O; Hrdinka M; Hajek R; Simicek M
Nat Commun; 2022 Nov; 13(1):6820. PubMed ID: 36357400
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
